Medherant’s testosterone TEPI Patch could become the first-in-class testosterone patch developed specifically for women
It will produce a comprehensive range of dosage forms including tablets, hard gelatin capsules, liquids, injectables, topicals, and beta-lactam products
The acquisition will follow the planned separation of Avidity’s early-stage precision cardiology programs into a new, independent company
The company's net income attributable to equity holders dropped to €2.80 billion from €2.82 billion last year
Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose
_256_384.jpg)
Tirzepatide is a prescription based the first and only dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors
The acquisition centers on ImCheck’s lead Phase I/II program, ICT01, a first-in-class monoclonal antibody targeting BTN3A
Gazyva/Gazyvaro is the only anti-CD20 monoclonal antibody to demonstrate a complete renal response benefit in lupus nephritis in a randomised phase III study
The expansion underscores Merck’s commitment to invest more than $70 billion in U.S. research, development and capital projects
Contera Pharma will receive an upfront payment and full research funding for each target under investigation
Subscribe To Our Newsletter & Stay Updated
